1201438-56-3

1201438-56-3 structure

Name: Duvelisib (IPI-145, INK1197)
Chemical Name: 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
CAS Number: 1201438-56-3
Molecular Formula: C₂₂H₁₇ClN₆O
Molecular Weight: 416.863
Catalog: Biochemical Inhibitor PI3K/Akt/mTOR inhibitor (PI3K/Akt/mTOR) PI3K inhibitor
Create Date: 2016-09-01 20:57:02
Modify Date: 2024-01-05 11:49:05
Duvelisib is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.

Name	8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
Synonyms	8-Chloro-2-phenyl-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone IPI-145 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]- UNII-610V23S0JI INK1197 INK-1197 duvelisib

Description	Duvelisib is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.
Related Catalog	Research Areas >> Cancer
Target	p110δ:2.5 nM (IC50) p110γ:27.4 nM (IC50) p110β:85 nM (IC50) p110α:1602 nM (IC50)
In Vitro	PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal cells[1].
References	[1]. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784-39795. [2]. G?ckeritz E, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234-42.

Density	1.5±0.1 g/cm3
Molecular Formula	C₂₂H₁₇ClN₆O
Molecular Weight	416.863
Exact Mass	416.115234
PSA	88.49000
LogP	4.60
Index of Refraction	1.757
Storage condition	-20°C

1350643-73-0

~94%

1201438-56-3

Literature: Ren, Pingda; Martin, Michael; Isbester, Paul; Lane, Benjamin S.; Kropp, Jason Patent: US2012/184568 A1, 2012 ; Location in patent: Page/Page column 83-84 ;

21327-86-6

1201438-56-3

Literature: WO2011/146882 A1, ; WO 2011/146882 A1

74497-02-2

1201438-56-3

Literature: WO2011/146882 A1, ; WO 2011/146882 A1

1386861-46-6

1201438-56-3

Literature: WO2011/146882 A1, ; WO 2011/146882 A1

89894-44-0

1201438-56-3

Literature: US2012/184568 A1, ;

1386861-47-7

1201438-56-3

Literature: US2012/184568 A1, ;

1350643-72-9

1201438-56-3

Literature: WO2011/146882 A1, ; WO 2011/146882 A1

87-42-3

1201438-56-3

Literature: US2012/184568 A1, ;

1350643-72-9

7306-68-5

1201438-56-3

Literature: US2012/184568 A1, ;

Precursor 6
1350643-73-0 21327-86-6 1386861-46-6 89894-44-0
87-42-3 7306-68-5
DownStream 0

1201438-56-3	1261590-48-0
1693758-51-8	1872435-10-3
88650-97-9	94349-28-7
93050-80-7	66057-80-5
75234-41-2	742092-03-1
1158522-08-7	940364-43-2
134104-43-1	1249476-17-2
131615-57-1	1498646-26-6
6906-52-1	1337458-75-9
1071727-56-4	930439-75-1